The DOI matches its Crossref record.
Treatment of normal individuals with granulocyte‐colony‐stimulating factor: donor experiences and the effects on peripheral blood CD34+ cell counts and on the collection of peripheral blood stem cells
Abstract
BACKGROUND: Granulocyte‐colony‐stimulating factor (G‐CSF) has been used in patients to increase the level of circulating hematopoietic progenitors. Although G‐CSF has been administered to some healthy individuals, the kinetics of mobilization of peripheral blood stem cells (PBSCs), the optimum dose schedule and the incidence and nature of adverse reactions in normal individuals are not completely defined. STUDY DESIGN AND METHODS: Normal individuals (n = 102) who received G‐ CSF for 5 or 10 days at doses of 2, 5, 7.5, or 10 micrograms per kg per day were studied. The subjects were observed for symptoms and physical changes, and blood samples were obtained for a variety of laboratory tests. After 5 or 10 days of G‐CSF treatment, PBSCs were collected by apheresis and analyzed. RESULTS: Overall, 89 percent of the individuals completed the 5‐day treatment protocol and 88 percent completed the 10‐ day protocol without modification of the dose of G‐CSF administered. Ninety percent of donors experienced some side effect of G‐CSF. The most frequent effects noted were bone pain (83%), headache (39%), body aches (23%), fatigue (14%), and nausea and/or vomiting (12%). The dose of G‐CSF administered directly affected the proportion of people with bone pain (p = 0.025) or body aches (p = 0.045) or who were feeling hot or having night sweats (p = 0.02) or taking analgesics (p = 0.01). With the 5‐day dose schedule, several changes in serum chemistries occurred, including increases in alkaline phosphatase (p = 0.001), alanine aminotransferase (p = 0.0013), lactate dehydrogenase (p = 0.0001), and sodium (p = 0.0001). Decreases occurred in glucose (p = 0.045), potassium (p = 0.0004), bilirubin (p = 0.001), and blood urea nitrogen (p = 0.0017). In donors who received G‐CSF for 5 days, the absolute neutrophil count was increased after one G‐CSF dose, and it reached a maximum on Day 6, as did the number of CD34+ cells (64.6 +/− 55.9 × 10(6) cells/L). In those same donors, the platelet count after apheresis on Day 6 was 32 +/− 13 percent lower than pretreatment values (250 +/− 42 × 10(9) cells/L). In donors receiving G‐CSF for 10 days, the neutrophil count reached a maximum on Day 8, but the number of CD34+ cells peaked on Day 6 (58.3 +/− 52.1 × 10(5) cells/L) and then declined. The platelet count decreased from pretreatment values by 28 +/− 12 percent prior to apheresis on Day 11. When individuals were treated for 5 days with G‐CSF, the quantity of CD34+ cells collected was directly related to the G‐CSF dose. When 5 micrograms per kg per day was given, 2.80 +/− 1.81 × 10(8) cells were collected, compared with collection of 4.67 +/− 3.11 × 10(8) cells when 10 micrograms per kg per day was given (p = 0.04). More important, PBSCs collected after 10 days of G‐CSF administration (5 micrograms/kg/day) had significantly fewer CD34+ cells (0.82 +/− 0.37 × 10(8) cells, p = 0.01) than did PBSCs collected after 5 days of G‐CSF (5 micrograms/kg/day). CONCLUSION: Most normal donors receiving G‐CSF experience side effects, but these are mild to moderate in degree. Some alterations in blood chemistries occur, but none were clinically serious. Because of the symptoms associated with G‐CSF, these individuals must be monitored closely. The treatment of normal donors with G‐CSF for more than 5 days significantly decreased the number of circulating CD34+ cells and the quantity collected by apheresis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Körbling, M., & Anderlini, P. (2001) · Blood · doi:10.1182/blood.v98.10.2900 · Cited by 361
Lévesque, J.-P., Hendy, J., Takamatsu, Y., Williams, B., Winkler, I. G., & Simmons, P. J. (2002) · Experimental Hematology · doi:10.1016/s0301-472x(02)00788-9 · Cited by 289
The endosteal ‘osteoblastic’ niche and its role in hematopoietic stem cell homing and mobilization
Lévesque, J.-P., Helwani, F. M., & Winkler, I. G. (2010) · Leukemia · doi:10.1038/leu.2010.214 · Cited by 268
Organ-on-a-chip model of vascularized human bone marrow niches
Glaser, D. E., Curtis, M. B., Sariano, P. A., Rollins, Z. A., Shergill, B. S., Anand, A., Deely, A. M., Shirure, V. S., Anderson, L., Lowen, J. M., et al. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2021.121245 · Cited by 146
Complications of donor apheresis
Winters, J. L. (2006) · Journal of Clinical Apheresis · doi:10.1002/jca.20039 · Cited by 103
Metadata
- Authors
- Stroncek, D. F., Clay, M. E., Petzoldt, M. L., Smith, J., Jaszcz, W., Oldham, F. B., & McCullough, J.
- Venue
- Transfusion
- Publisher
- Wiley
- Published
- 1996-07
- Volume
- 36
- Issue
- 7
- Pages
- 601-610
- ISSN
- 0041-1132 (ISSN-L)
- 1537-2995
- OpenAlex
- W2118168943
- Cited by
- 232
- References
- 0
- FWCI
- 7.28
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Treatment of normal individuals with granulocyte‐colony‐stimulating factor: donor experiences and the effects on peripheral blood CD34+ cell counts and on the collection of peripheral blood stem cells. https://app.cochat.ai/papers/10.1046/j.1537-2995.1996.36796323059.x
- The paper
- Stroncek, D. F., Clay, M. E., Petzoldt, M. L., Smith, J., Jaszcz, W., Oldham, F. B., & McCullough, J. (1996). Treatment of normal individuals with granulocyte‐colony‐stimulating factor: donor experiences and the effects on peripheral blood CD34+ cell counts and on the collection of peripheral blood stem cells. Transfusion. https://doi.org/10.1046/j.1537-2995.1996.36796323059.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.